Edwyn logo

Edwyn

Find Companies
Find Companies
Dashboard
Find Companies...

Footer

EdwynEdwyn

Conduct a Professional Comparative analysis in seconds. Empowering your financial decisions with data-driven insights.

Subscribe to our newsletter

Company

  • About
  • Contact us
  • Register

Legal

  • Privacy
  • Terms

Guides

  • What is Enterprise Value?
  • How much is my company worth?

© 2025 Edwyn, LLC. All rights reserved.

Edwyn logo

Edwyn

Enterprise Value
EV Calculator
Help
What is Enterprise Value?
    Log in
    Log in
    Tesla, Inc.
    Apple Inc.
    NVIDIA
    Walmart
    Microsoft
    No valuations found.
    Log in to save
    Edwyn logo

    Edwyn

    Tesla, Inc.
    Apple Inc.
    NVIDIA
    Walmart
    Microsoft
    No valuations found.
    BIO-RAD LABORATORIES, INC. (BIO, BIO-B)
    Income
    Balance Sheet
    Market Cap
    $8B
    Latest price
    $301.59
    0.58%
    Dollar Amounts
    USD (Millions)
    Metric20202021202220232024
    Revenue$2,546$2,923$2,802$2,671$2,567
    Gross Profit$1,438$1,641$1,567$1,427$1,379
    Operating Income$411$489$483$338$269
    Net Income$3,806$4,246-$3,628-$637-$1,844
    Showing latest financials
    Data in millions of USD
    Doing some research...

    Commentary on BIO-RAD LABORATORIES, INC. Performance

    Over the five-year period, BIO‑RAD LABORATORIES, INC. shows some mixed financial trends. Revenue increased by roughly 15% from $2,545.6 million in 2020 to a peak of $2,922.5 million in 2021, but then it began a gradual decline, sliding to $2,566.5 million by 2024. Gross profit follows a similar trajectory, rising to $1,640.66 million in 2021 before decreasing gradually to $1,378.9 million in 2024. Operating income also registered growth in early years, increasing from about $411 million in 2020 to nearly $489 million in 2021, but then fell steadily to $269 million by 2024, indicating a gradual erosion of operational efficiency that could be linked to rising costs or pricing pressures in the life sciences sector. A striking volatility emerges in the net income figures. Notably, net income was exceptionally high in 2020 and 2021, at $3,806.27 million and $4,245.90 million respectively, but then swung dramatically into the red with a loss of $3,627.54 million in 2022, remaining negative in 2023 (-$637.32 million) and 2024 (-$1,844.2 million). This more-than-100% drop between 2021 and 2022 suggests significant, one-off expenses or adverse market factors that might include changes in regulatory environments, restructuring costs, or market volatility impacting the diagnostic and life science research industry. Overall, while the core operating performance remains positive, the steep decline in net income raises concerns about net profitability sustainability, warranting a deeper investigation into the drivers behind these significant swings.

    This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.